Dr. Ron Greeno Joins Cizzle Bio as Chief Medical Officer
Cizzle Bio is excited to welcome Ron Greeno, MD, MHM, FCCP, as our Chief Medical Officer (CMO). A seasoned physician executive and healthcare innovator, Dr. Greeno brings 30 years of leadership experience in physician services management, federal healthcare policy, and value-based care models. His expertise in clinical strategy, policy development, and healthcare payment innovation will play a crucial role in advancing Cizzle Bio’s mission to revolutionize early cancer detection.
A Proven Leader in Healthcare Strategy & Policy
Dr. Greeno’s illustrious career includes founding Cogent Healthcare, where he served as Executive Vice President for Strategy and Chief Medical Officer until its merger with Sound Physicians. His leadership continued in executive roles at IPC and TeamHealth, helping to shape hospitalist medicine and physician management on a national scale.
As a board-certified physician in internal medicine, pulmonary medicine, and critical care, Dr. Greeno has dedicated his career to improving patient outcomes, advancing healthcare policy, and optimizing care delivery models.
Shaping the Future of U.S. Healthcare Policy
Beyond his clinical leadership, Dr. Greeno has been a key figure in healthcare policy and government relations:
Senior Advisor for Government Relations at the Society of Hospital Medicine (SHM)
Former President of SHM, representing 50,000 hospitalist physicians nationwide
Works closely with Capitol Hill, Medicare, and the Center for Medicare & Medicaid Innovation (CMMI)
Focuses on innovative healthcare payment models to enhance care quality and reduce costs
His expertise in value-based care and alternative payment models aligns with Cizzle Bio’s vision to enhance early cancer detection and patient access to cutting-edge diagnostics.
Driving Cizzle Bio’s Medical Strategy
As Chief Medical Officer, Dr. Greeno will provide strategic medical leadership to help:
Advance biomarker-driven diagnostics for early cancer detection
Navigate reimbursement and healthcare payment models for greater accessibility
Expand partnerships with hospitals, payers, and regulatory bodies to drive adoption of Cizzle Bio’s technologies
Bill Behnke, Cizzle Bio’s Chairman and CEO, shared his enthusiasm about Dr. Greeno’s appointment:
“We are thrilled to welcome Dr. Ron Greeno to Cizzle Bio as our Chief Medical Officer. Having known Dr. Greeno for more than 25 years as an innovator and leader in pulmonary critical care, I am confident that his exceptional background as a seasoned physician executive, healthcare strategist, and clinical thought leader makes him the perfect fit to lead our medical strategy. With more than three decades of experience across clinical practice, healthcare policy, and value-based care, Dr. Greeno’s deep expertise will be instrumental in expanding strategic partnerships that drive our mission to revolutionize early cancer detection. His leadership will not only accelerate the adoption of our biomarker-driven diagnostics but also help shape the future of patient-centered care. We are excited about the transformative impact his vision will have on Cizzle Bio’s growth and our ongoing commitment to improving healthcare outcomes for patients worldwide.”
His leadership will ensure Cizzle Bio remains at the forefront of innovation in cancer diagnostics, healthcare policy, and patient-centered care.
Looking Ahead
Dr. Greeno’s addition marks a pivotal moment as Cizzle Bio expands its presence in the healthcare and diagnostics landscape. His expertise in clinical strategy, physician services, and healthcare policy will be instrumental in accelerating the adoption of biomarker-based early detection solutions.
We are thrilled to have Dr. Ron Greeno on board and look forward to the groundbreaking advancements his leadership will bring.
Please join us in welcoming Dr. Ron Greeno to the Cizzle Bio team!
